Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence

Rodrigues, Nelson B.; McIntyre, Roger S.; Lipsitz, Orly; Danielle, S.; Lee, Yena; Gill, Hartej; Majeed, Amna; Phan, Lee; Nasri, Flora; Ho, Roger; Lin, Kangguang; Subramaniapillai, Mehala; Kratiuk, Kevin; Mansur, Rodrigo B.; Rosenblat, Joshua D.

doi:10.1016/j.jad.2020.07.083

Cited by 37 publications

(31 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent retrospective post-hoc analysis of over 200 participants with treatment-resistant depression in the course of MDD or BD revealed a significant reduction in the SHAPS score during and after four ketamine infusions. The authors also found that improvements in depressive symptoms, suicidal ideation, and anxiety symptoms were mediated by a reduction in anhedonic symptoms since anhedonia accounted for 26% of the variance in depressive score improvements measured with QIDS 16 ( 18 ).…”

Section: Discussionmentioning

confidence: 95%

“…Taken together, these findings suggest that the glutamatergic system and its downstream modulation of dopaminergic activity may be one potential route of the antianhedonic efficacy of ketamine in both unipolar and bipolar treatment resistant depression (TRD). Limited evidence on the effect of IV ketamine on anhedonia in humans supports this hypothesis (16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

et al. 2021

View full text Add to dashboard Cite

Anhedonia constitutes one of the main symptoms of depressive episode. It correlates with suicidality and significantly effects the quality of patient's lives. Available treatments are not sufficient against this group of symptoms. Ketamine is a novel, rapid acting strategy for treatment resistant depression. Here we report the change in symptoms of anhedonia measured by Snaith-Hamilton Pleasure Scale as an effect of eight ketamine infusions as an add-on treatment in 42 patients with treatment resistant depression. We also determined the effect of this change on the severity of depressive symptoms measured by Inventory for Depression Symptomatology-Self Report 30-Item (IDS-SR 30). We have observed statistically significant decrease in the level of anhedonia during ketamine treatment. After adjusting for potential confounders we have found that significant reduction in Snaith-Hamilton Pleasure Scale (SHAPS) after each infusion and 1 week post treatment was observed only among patients who did not use benzodiazepines. The reduction in symptoms of anhedonia mediates the antidepressive effect of ketamine. The results need replication in a larger randomized placebo controlled trial.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Ketamine, as a dissociative anesthetic, is currently evaluated as a rapid-acting antidepressant. In addition to the rapid effect on depressive symptoms, ketamine also has rapid and robust effects on anhedonia symptoms (1,9,10) and suicidal ideation (11)(12)(13) in treatment-refractory BD and MDD. When compared with placebo, a single ketamine infusion could rapidly ameliorate anhedonia symptoms in individuals suffering from treatmentrefractory BD; the reduction in anhedonia symptoms occurred within 40 min and lasted up to 14 days (10).…”

Section: Introductionmentioning

confidence: 99%

Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression

Zheng

Zhou

et al. 2021

Front. Psychiatry

View full text Add to dashboard Cite

Objectives: To first explore the role of plasma vascular endothelial growth factor (VEGF) concentrations in ketamine's antianhedonic effects, focusing on Chinese patients with treatment-refractory depression (TRD).Methods: Seventy-eight patients with treatment-refractory major depressive disorder (MDD) or bipolar disorder (BD) were treated with six ketamine infusions (0.5 mg/kg). Levels of anhedonia were measured using the Montgomery–Åsberg Depression Rating Scale (MADRS) anhedonia item at baseline, day 13 and 26. Plasma VEGF concentrations were examined at the same time points as the MADRS.Results: Despite a significant reduction in anhedonia symptoms in individuals with treatment-refractory MDD (n = 59) or BD (n = 19) after they received repeated-dose ketamine infusions (p < 0.05), no significant changes in plasma VEGF concentrations were found at day 13 when compared to baseline (p > 0.05). The alteration of plasma VEGF concentrations did not differ between antianhedonic responders and non-responders at days 13 and 26 (all ps > 0.05). Additionally, no significant correlations were observed between the antianhedonic response to ketamine and plasma VEGF concentrations (all ps > 0.05).Conclusion: This preliminary study suggests that the antianhedonic effects of ketamine are not mediated by VEGF.

show abstract

“…In the begging of 2000, Berman et al (BERMAN et al, 2000) were the first to reveal that the infusion of a subanesthetic dose of ketamine exerts robust rapid (within 2 h following administration) and sustained antidepressant effect lasting for 3 days in the depressed patient (BERMAN et al, 2000). Subsequent clinical studies evidenced similar rapid and sustained (7 days on average) antidepressant effect in patients (CUSIN et al, 2016;DIAZGRANADOS et al, 2010;FREEMAN et al, 2020;GHASEMI et al, 2013;KRYSTAL et al, 1994;O'BRIEN et al, 2019;RODRIGUES et al, 2020;ZARATE et al, 2006;ZARATE JR et al, 2012). Moreover, ketamine exerts an antidepressant effect in treatment-resistant depression patients and reduces suicide ideation (DIAZGRANADOS et al, 2010;MURROUGH et al, 2015;O'BRIEN et al, 2019;RODRIGUES et al, 2020).…”

Section: Ketaminementioning

confidence: 86%

“…Subsequent clinical studies evidenced similar rapid and sustained (7 days on average) antidepressant effect in patients (CUSIN et al, 2016;DIAZGRANADOS et al, 2010;FREEMAN et al, 2020;GHASEMI et al, 2013;KRYSTAL et al, 1994;O'BRIEN et al, 2019;RODRIGUES et al, 2020;ZARATE et al, 2006;ZARATE JR et al, 2012). Moreover, ketamine exerts an antidepressant effect in treatment-resistant depression patients and reduces suicide ideation (DIAZGRANADOS et al, 2010;MURROUGH et al, 2015;O'BRIEN et al, 2019;RODRIGUES et al, 2020). In this sense, ketamine opens a new era for the treatment of depression with a fast-acting antidepressant class, with non-monoaminergic mechanism.…”

Section: Ketaminementioning

confidence: 86%

Behavioural and molecular effects induced by Cannabidiol in animal models of depression

Silote¹

View full text Add to dashboard Cite

show abstract

Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence

Cited by 37 publications

References 34 publications

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression

Behavioural and molecular effects induced by Cannabidiol in animal models of depression

Contact Info

Product

Resources

About